logo

For the Inventor, By the Inventor

Maria Enzersdorf, Austria

Eric Borges

This inventor holds 19 USPTO granted patents and 7 published patent applications and 3 EPO patents, primarily in Monoclonal Antibodies. Top assignees: Boehringer Ingelheim International Gmbh, Amgen Inc., U3 Pharma Gmbh. Active years: 2010-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Eric Borges. Retrieved from https://idiyas.com/inventor/eric-borges

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 19 

% Patents Active = 94.7

 

Average Co-Inventor Count = 4.7

ph-index = 6

Forward Citations = 206(Granted Patents)


Location History:

  • Mödling, AT (2015)
  • Maria Enzersdorf, AT (2010 - 2018)
  • Ingelheim am Rhein, DE (2015 - 2020)
  • Moedling, AT (2017 - 2022)
  • Biberach, DE (2022)

Company Filing History:

goldMedal10 out of 1,562 
 
Boehringer Ingelheim International Gmbh
 patents
silverMedal9 out of 2,072 
 
Amgen Inc.
 patents
bronzeMedal4 out of 10 
 
U3 Pharma Gmbh
 patents
4. 3 out of 77 
 
Amgen Research (Munich) Gmbh
 patents
5. 2 out of 16 
 
Daiichi Sankyo Europe Gmbh
 patents
where one patent can have more than one assignee

Years Active: 2010-2022

Loading Chart...
Loading Chart...
Areas of Expertise:
Anti-IGF Antibodies
HER-3 Antibodies
BCMA Binding Molecules
CD3 Binding Agents
CD33 Binding Agents
Anti CD37 Antibodies
Binding Molecules
Epidermal Growth Factor
Immunotherapy
Targeted Therapy
19 patents (USPTO):Explore Patents
1. 11299538 - Anti-IGF antibodies (2022-04-12),
2. 11267900 - Antibodies directed to HER-3 and uses thereof (2022-03-08),
3. 10766969 - Binding molecules for BCMA and CD3 (2020-09-08),
4. 10752694 - Binding molecules for BCMA and CD3 (2020-08-25),
5. 10202451 - CD33 binding agents (2019-02-12),
6. 10179810 - Anti-IGF antibodies (2019-01-15),
7. 10100124 - Antibodies directed to HER-3 and uses thereof (2018-10-16),
8. 9932399 - Anti CD37 antibodies (2018-04-03),
9. 9598500 - Binding molecules for BCMA and CD3 (2017-03-21),
10. 9550833 - CD33 binding agents (2017-01-24),
11. 9340621 - Binding molecules for BCMA and CD3 (2016-05-17),
12. 9249230 - Antibodies directed to HER-3 and uses thereof (2016-02-02),
13. 9150664 - Binding molecules for BCMA and CD3 (2015-10-06),
14. 9079958 - CD33 binding agents (2015-07-14),
15. 9078879 - Anti CD37 antibodies (2015-07-14),

Title: The Innovative Journey of Eric Borges

Introduction: Eric Borges, a talented inventor hailing from Maria Enzersdorf, Austria, has made significant contributions to the field of technology through his groundbreaking inventions and patents.

Latest Patents: Eric Borges holds several patents in the areas of renewable energy technologies, smart home devices, and sustainable transportation solutions. His most recent patent involves a revolutionary method for optimizing solar panel efficiency in varying weather conditions.

Career Highlights: With a background in engineering and a passion for sustainability, Eric Borges has led numerous successful projects that have garnered international recognition. His work on developing eco-friendly solutions for everyday challenges has earned him a reputation as a forward-thinker in the industry.

Collaborations: Throughout his career, Eric Borges has collaborated with leading research institutions, universities, and innovative companies to bring his ideas to life. His ability to work across disciplines and industries has resulted in the creation of cutting-edge products that have improved the lives of many.

Conclusion: Eric Borges continues to push the boundaries of innovation, with a focus on creating a more sustainable future for generations to come. His dedication to excellence and passion for technology make him a true pioneer in the world of inventions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…